๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for T Cells

Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants NCT07636551NA1 site๐Ÿ“ Antwerp Institute of Tropical Medicine, Belgium ยท Tests: Skin punch biopsy, Blood samples Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07359014NA1 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Dual CD19/BCMA CAR-T T-cell Therapy in Patients With PML NCT06990087Phase 27 sites๐Ÿ“ Mรผnchen๐Ÿ“ Marburg๐Ÿ“ Hanover Hannover Medical School ยท Tests: Application of T-lymphocytes ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) NCT06415487Phase 19 sites๐Ÿ“ San Diego๐Ÿ“ Denver๐Ÿ“ Nashville Acepodia Biotech, Inc. ยท Tests: Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia NCT05281809Phase 21 site๐Ÿ“ Pittsburgh John Lister ยท Tests: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites๐Ÿ“ Coral Gables๐Ÿ“ Deerfield Beach๐Ÿ“ Miami University of Miami ยท Tests: Selinexor, Venetoclax, Dexamethasone GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma NCT05587543EARLY Phase 11 site๐Ÿ“ Shanghai Fudan University ยท Tests: PK Blood Collection, CAR, TCR CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases NCT05827835Phase 1, Phase 21 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients NCT05141058Phase 12 sites๐Ÿ“ Washington D.C.๐Ÿ“ Baltimore Children's National Research Institute ยท Tests: Coronavirus-specific T cell (CST) MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site๐Ÿ“ Scottsdale Mayo Clinic ยท Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108Phase 21 site๐Ÿ“ Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Scโ€ฆ ยท Tests: Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies NCT07106749Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CD180 CART Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies NCT07284433Phase 1, Phase 213 sites๐Ÿ“ Chicago๐Ÿ“ Evanston๐Ÿ“ Providence AvenCell Therapeutics, Inc. ยท Tests: Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), Allo-QuadCAR01-T Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia NCT07144020EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: CD117 CAR T-cells The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma NCT07645690EARLY Phase 13 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: CLEAR CAR-T cell injection A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. NCT07593820Phase 12 sites๐Ÿ“ Barcelona๐Ÿ“ Barcelona Vall d'Hebron Institute of Oncology ยท Tests: p95HER2.CAR-TECH2Me Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC NCT07145450Phase 1, Phase 210 sites๐Ÿ“ Copenhagen๐Ÿ“ Berlin๐Ÿ“ Dresden Anocca AB ยท Tests: ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles), ANOC-002 (TCR-T cells targeting โ€ฆ Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas NCT06176690Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: C7R.CD30.CAR-EBVST cells Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma NCT07763210Phase 21 site๐Ÿ“ Nashville Vanderbilt-Ingram Cancer Center ยท Tests: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228NA1 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: CAR-T cells, Venetoclax, Olverembatinib SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites๐Ÿ“ Denver๐Ÿ“ Atlanta๐Ÿ“ Fairway Verismo Therapeutics ยท Tests: SynKIR-310 MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers NCT03198052Phase 12 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFฮฒ, HER2, Lewis-Y, AXL, or EGFR IVIG for Infection Prevention After CAR-T-Cell Therapy NCT05952804Phase 27 sites๐Ÿ“ Duarte๐Ÿ“ Miami๐Ÿ“ Tampa Fred Hutchinson Cancer Center ยท Tests: Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline, Biospecimen Collection, Survโ€ฆ Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rฮฑ2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas NCT07544992Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDGโ€ฆ Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial NCT07227571Phase 11 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine, Cyclophosphamide, Echocardiography Test IMA402 T Cell-Engaging Receptor Molecule (TCERยฎ) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg๐Ÿ“ Mannheim Immatics Biotechnologies GmbH ยท Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. NCT07203404EARLY Phase 11 site๐Ÿ“ Shanghai Nanjing Bioheng Biotech Co., Ltd. ยท Tests: RD06-05 CART Cell Injection
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy